參考文獻/References:
[1] AHMED M.Gastrointestinal neuroendocrine in the tumors in 2020[J].World journal of gastrointestnal oncology,2020,12(8):791-807.
[2] WEILER R,FEICHTINGER H,SCHMID K W,et al.Chromogranin A and B and secretogranin Ⅱ in bronchial and intestinal carcinoids[J].Virchows Arch A Pathol Anat Histopathol,1987,412(2):103-109.
[3] 盛偉琪,周煒洵,陳杰,等.中國胃腸胰神經(jīng)內(nèi)分泌腫瘤病理診斷共識(2020版)[J].中華病理學雜志,2021,50(1):14-14.
[4] HUGUET I,GROSSMAN A B,O'TOOLE D.Changes in the epidemiology of neuroendocrine tumours[J].Neuroendocrinology,2017,104(2):105-111.
[5] DASARI A,SHEN C,HALPERIN D,et al.Trends in the incidence,prevalence,and survival outcomes in patients with neuroendocrine tumors in the United States[J].JAMA Oncol,2017,3(10):1335-1342.
[6] 李曉玲,周金釗,王衡,等.177例胃腸神經(jīng)內(nèi)分泌腫瘤的臨床病理分析[J].廣東醫(yī)科大學學報,2021(3):357-360.
[7] 李燕維,倪慕蘭,王宇航.INSM1在消化道神經(jīng)內(nèi)分泌腫瘤診斷中的應用價值[J].醫(yī)學理論與實踐,2023(18):3176-3178.
[8] 徐天銘,程小韻,閻鵬光,等.直腸神經(jīng)內(nèi)分泌腫瘤臨床及病理特征分析[J].中華內(nèi)科雜志,2021,60(10):886-890.
[9] ISCHIA R,GASSER R W,FISCHER-COLBRIE R,et al.Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients[J].J Clin Endocrinol Metab,2000,85(1):355-360.
[10] Le GALL F,VALLET V S,THOMAS D,et al.Immunohistochemical study of secretogranin Ⅱ in 62 neuroendocrine tumours of the digestive tract and of the pancreas in comparison with other granins[J].Pathol Res Pract,1997,193(3):179-185.
[11] MONTERO-H M,VAINGANKAR S,ELIAS S,et al.Chromogranins A and B and secretogranin Ⅱ:evolutionary and functional aspects[J].Acta Physiol(Oxf),2008,192(2):309-324.
[12] TOPCAGIC J,FELDMAN R,GHAZPLPOUR A,et al.Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas[J].PLoS One,2018,13(1):e0191244.
[13] 廖志曉,鄧躍揚,周京旭,等.結(jié)直腸神經(jīng)內(nèi)分泌腫瘤預后列線圖的構(gòu)建[J].重慶醫(yī)學,2023,20:3081-3087.
[14] 閆玉玲.Syn、CgA、Ki67在胃腸胰神經(jīng)內(nèi)分泌腫瘤患者中的表達及其與臨床特征的相關性[J].中國民康醫(yī)學,2021(19):1-4.
[15] PORTELA-G G M,STRIDSBERG M,GRIMELIUS L,et al.Expression of chromogranins A,B,and C(secretogranin Ⅱ)in human adrenal medulla and in benign and malignant pheochromocytomas an immunohistochemical study with region-specific antibodies[J].APMIS,2004,112(10):663-673.
[16] AL-RISI E S,AL-ESSRY F S,MULA-ABED W S.Chromogranin A as a biochemical marker for neuroendocrine tumors:a single center experience at Royal Hospital[J].Oman Med J,2017,32(5):365-370.
[17] YOO S H,CHU S Y,KIM K D,et al.Presence of secretogranin Ⅱ and high-capacity,low-affinity Ca2+ storage role in nucleoplasmic Ca2+ store vesicles[J].Biochemistry,2007,46(50):14663-14671.
[18] PARK H Y,SO S H,LEE W B,et al.Purification,pH-dependent conformational change,aggregation,and secretory granule membrane binding property of secretogranin Ⅱ(chromogranin C)[J].Biochemistry,2002,41(4):1259-1266.
[19] STRIDSBERG M,ERIKSSON B,JANSON E T.Measure-ments of secretogranins Ⅱ,Ⅲ,Ⅳ and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours[J].Regul Pept,2008,148(1/3):95-98.